Empatica raises $35M Series C for wrist-based seizure detection expansion
Summary
Milan-based Empatica secured $35M Series C led by Sofinnova Partners, with Boehringer Ingelheim Venture Fund and Novo Holdings, to expand their FDA-cleared EmbracePlus wristband seizure detection platform. Funds support pediatric epilepsy clinical studies, expansion of their clinical research platform for remote epilepsy monitoring in trials, and development of next-generation dry EEG wristband electrodes.
Why it matters
Empatica's FDA-cleared wristband seizure detection has genuine commercial traction in epilepsy clinical research. The dry EEG electrode development is the key next step — if successful, it would combine autonomic and neural seizure biomarkers in a single consumer wearable with substantially improved sensitivity over PPG alone.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial